| 2026-06-09 | Press release | Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern Time |
| 2026-06-09 | Press release | PDF of Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern Time |
| 2026-05-14 | Press release | Shuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Minin |
| 2026-05-01 | Press release | United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation |
| 2026-04-30 | Press release | Shuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin Miner |
| 2026-03-27 | Press release | RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows |
| 2026-03-26 | Press release | Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows |
| 2026-03-06 | Press release | Shuttle Pharmaceuticals Announces $3.5 Million Public Offering |
| 2026-01-13 | Press release | Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs – and Why Molecule.ai’s Drug Disc |
| 2025-11-21 | Press release | Shuttle Pharmaceuticals Acquires AI Health Platform |
| 2025-11-03 | Press release | Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00 |
| 2025-10-21 | Press release | Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform |
| 2025-10-10 | Press release | Shuttle Executes LOI with Molecule.ai |
| 2025-06-24 | Press release | Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market |
| 2025-06-20 | Press release | Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market |
| 2025-05-15 | Press release | Shuttle Pharma Provides Corporate Update |
| 2025-04-21 | Press release | Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025 |
| 2025-03-13 | Press release | Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering |
| 2025-03-12 | Press release | Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering |
| 2025-02-26 | Press release | Shuttle Pharma Provides Corporate Update and Reports 2024 Results |
| 2025-01-21 | Press release | Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Pat |
| 2025-01-07 | Press release | Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 |
| 2024-12-19 | Press release | Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA |
| 2024-11-26 | Press release | Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Gl |
| 2024-11-13 | Press release | Shuttle Pharma Provides Third Quarter 2024 Corporate Update |
| 2024-10-29 | Press release | Shuttle Pharma Pays Off Senior Secured Convertible Note |
| 2024-10-29 | Press release | Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasd |
| 2024-10-28 | Press release | Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024 |
| 2024-09-16 | Press release | Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Gliob |
| 2024-09-04 | Press release | Shuttle Pharma Provides Second Quarter 2024 Corporate Update |
| 2024-08-28 | Press release | Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement |
| 2024-08-26 | Press release | Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1) |
| 2024-08-14 | Press release | Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Gliob |
| 2024-07-19 | Press release | Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substanti |